The mutations leading to increased cancer cell survival, discussed earlier, are engaged in the activation of oncogenic pathways, including WNT/beta-catenin, STAT3, PI3K/PTEN/AKT/mTOR, RAS/RAF/MAPK or NFκB (68). This evidence concerns the gene STAT3 and cancer.